An Antitrust Analysis on Reverse Payment Settlements
碩士 === 逢甲大學 === 財經法律研究所 === 102 === Reverse payment settlements in the pharmaceutical industry is an unforeseen consequence under the Hatch Waxman Act enacted in 1984, for the purpose of increasing innovation and accelerating the entry of generic drugs. Despite the underlying intent, the act created...
Main Author: | 張育菁 |
---|---|
Other Authors: | 林廷機 |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/34009402337753772525 |
Similar Items
-
An Analysis of Antitrust Scrutiny on Reverse-Payment Consent - Focus on ACTAVIS Case
by: Hung-Chan Hsiao, et al.
Published: (2015) -
Reasonable Restrictions to Medical Patents-Focus on the Antitrust Regulations Involving with the Reverse-Payment Agreement Arose from Patent Infringement
by: Wu, Li-Yin, et al.
Published: (2014) -
The Legal Research of Payment, Clearing and Settlement
by: Yu-Ting Lin, et al.
Published: (2006) -
Payment Card Systems as an Example of Two-sided Markets – a Challenge for Antitrust Authorities
by: Katarzyna Tosza
Published: (2009-11-01) -
The payment Settlement System
by: Chen kuang hui, et al.
Published: (2007)